OBI Pharma
OBI Pharma is a Taiwanese biotech that turns the tumour sugar Globo H into cancer vaccines and antibody-drug conjugates, best known for the breast cancer vaccine adagloxad simolenin.
Overview
OBI Pharma, listed on the Taipei Exchange, develops therapies against Globo-series glycolipids that are over-expressed on many epithelial tumours. Adagloxad simolenin (OBI-822), a Globo H vaccine, is in a phase 3 trial in Globo H-high triple-negative breast cancer. Its pipeline also includes OBI-992, a TROP2 antibody-drug conjugate, and OBI-902, a Globo H-directed conjugate, together with the ThioBridge linker platform.
Scorecard
All companies- phase 3 +3
- phase 1/2 +2
- modalities +4
- registry trials +4
Adagloxad simolenin is OBI Pharma's vaccine against the tumour sugar Globo H, in the phase 3 GLORIA trial as adjuvant treatment for triple-negative breast cancer that expresses the antigen.
OBI-902 is an antibody-drug conjugate from OBI Pharma, Inc, in registered phase 2 trials for metastatic cancer.
OBI-992 is an antibody-drug conjugate from OBI Pharma, Inc, in registered phase 2 trials for metastatic cancer.